JavaScript is disabled in your browser. Please enable JavaScript to view this website.

C-X-C chemokine receptor type 4 (CXCR4)

CXCR4 target protein structure

Figure 1: CXCR4 target protein structure.

CXCR4 Target Introduction

Protein Function

Protein Expression

Protein Localization

CXCR4 ICC experimental result image, Anti-CXCR4 antibody [UMB2] (ab124824). Green: CXCR4; Red: Tubulin; Blue: DAPI.

Figure 2: CXCR4 ICC experimental result image, Anti-CXCR4 antibody [UMB2] (ab124824). Green: CXCR4; Red: Tubulin; Blue: DAPI.

Isoforms & Post-translational modifications

Human (P61073): Isoform 1-2: 39-40 kDa (predicted)
Mouse (P70658): Isoform 1-2: 40 kDa (predicted)
Rat (O08565): 39 kDa (predicted)
Existence of post-translational modifications such as phosphorylation, disulfide bonding, glycosylation, ubiquitination, etc.

WB experiment tips

Precautions

Positive control

Example of results

WB-Anti-CXCR4 antibody [UMB2] (ab124824).

Figure 3: WB-Anti-CXCR4 antibody [UMB2] (ab124824).

Lane 1: 15 µg HeLa whole cell lysate.
Lanes 2-3: 15 µg Jurkat whole cell lysate.
Predicted band size: 39 kDa.
Actual band size: 43 kDa.
Note: We recommend not boiling the samples after lysis.

WB-Anti-CXCR4 antibody [UMB2] (ab124824).

Figure 4: WB-Anti-CXCR4 antibody [UMB2] (ab124824).

Lane 1: 20 µg CHO whole cell lysate (negative control)
Lane 2: 20 µg Jurkat whole cell lysate
Lane 3: 20 µg Jurkat cell membrane extract
Lane 4: 20 µg Jurkat cell nuclear extract (negative control)

Predicted band size:  39 kDa
Actual band size: 41 kDa

Key control points

In the experiment, special attention should be given to key control points in addition to routine issues:

Sample preparation:

  1. Add a complex proteinase inhibitor to avoid degradation of the target protein.
  2. Keep the sample on ice throughout the sample preparation process.
  3. Determine the total protein concentration of the sample through Bradford analysis, Lowry analysis, or BCA analysis.

Electrophoresis:

  1. Load at least 20 μg total protein for electrophoresis.

Transferring:

  1. We recommend using Ponceau S staining after transferring to determine the success of the transfer.

References

  1. S K Gupta, K Pillarisetti. Cutting edge: CXCR4-Lo: molecular cloning and functional expression of a novel human CXCR4 splice variant. Comparative Study J Immunol. 1999 Sep 1;163(5):2368-72.
  2. Y Cao, Z R Hunter, X Liu, L Xu, G Yang, J Chen, C J Patterson, N Tsakmaklis, S Kanan, S Rodig, J J Castillo, S P Treon. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. Leukemia. 2015 Jan;29(1):169-76. doi: 10.1038/leu.2014.187. Epub 2014 Jun 10.
  3. Travis Lear, Sarah R Dunn, Alison C McKelvey, Aazrin Mir, John Evankovich, Bill B Chen, Yuan Liu. RING finger protein 113A regulates C-X-C chemokine receptor type 4 stability and signaling. Am J Physiol Cell Physiol. 2017 Nov 1;313(5):C584-C592. doi: 10.1152/ajpcell.00193.2017. Epub 2017 Oct 4.
  4. Vikas Saini, Adriano Marchese, Matthias Majetschak. CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J Biol Chem. 2010 May 14;285(20):15566-15576. doi: 10.1074/jbc.M110.103408. Epub 2010 Mar 12.
  5. K Triantafilou, M Triantafilou, R L Dedrick. A CD14-independent LPS receptor cluster. Nat Immunol. 2001 Apr;2(4):338-45. doi: 10.1038/86342.
  6. C K Lapham, J Ouyang, B Chandrasekhar, N Y Nguyen, D S Dimitrov, H Golding. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science. 1996 Oct 25;274(5287):602-5. doi: 10.1126/science.274.5287.602.